REQUEST A DEMO
Total
USD $0.00
Search more companies

Astrazeneca Czech Republic S.R.O. (Czech Republic)

Main Activities: Drugs and Druggists' Sundries Merchant Wholesalers
Full name: Astrazeneca Czech Republic S.R.O. Profile Updated: September 14, 2024
Buy our report for this company USD 29.95 Most recent financial data: 2021 Available in: English Download a sample report

AstraZeneca Czech Republic s.r.o. is a subsidiary of AstraZeneca, an international pharmaceutical company with its own research program focused on gastroenterology, anesthesiology, cardiovascular disease, oncology, CNS, infectious diseases, respiratory diseases, joint and bone diseases. The company was created in 1995 and is headquartered in Prague.

Headquarters
U Trezorky 921/2
Prague; The City of Prague; Postal Code: 15800

Contact Details: Purchase the Astrazeneca Czech Republic S.R.O. report to view the information.

Website: http://www.astrazeneca.cz

Basic Information
Total Employees:
Purchase the Astrazeneca Czech Republic S.R.O. report to view the information.
Outstanding Shares:
Purchase the Astrazeneca Czech Republic S.R.O. report to view the information.
Registered Capital:
Purchase the Astrazeneca Czech Republic S.R.O. report to view the information.
Financial Auditors:
Purchase the Astrazeneca Czech Republic S.R.O. report to view the information.
Incorporation Date:
June 13, 1995
Key Executives
Purchase this report to view the information.
Legal Representative
Ownership Details
Purchase this report to view the information.
100%
Company Performance
Financial values in the chart are available after Astrazeneca Czech Republic S.R.O. report is purchased.
Looking for more than just a company report?

EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.

Request a demo of the EMIS service
Key Financial Highlights
Annual growth percentages for latest two years in local currency CZK. Absolute financial data is included in the purchased report.
Net sales revenue
4.22%
Total operating revenue
4.24%
Operating profit (EBIT)
4.59%
EBITDA
26.65%
Net Profit (Loss) for the Period
-1.38%
Total assets
38.43%
Total equity
8.29%
Operating Profit Margin (ROS)
0.01%
Net Profit Margin
-0.11%
Return on Equity (ROE)
-0.75%
Quick Ratio
-0.33%
Cash Ratio
-0.06%

To view more information, Request a demonstration of the EMIS service

Buy this company report
Need ongoing access to company, industry or country information?